S&P Futures
4,161.75 -14.00 (-0.34%) Dow Futures
34,126.00 -80.00 (-0.23%) Nasdaq Futures
12,734.50 -42.25 (-0.33%) Russell 2000 Futures
1,969.20 -10.10 (-0.51%) Crude Oil
78.29 +1.15 (+1.49%) Gold
1,896.50 +11.70 (+0.62%)
AstraZeneca PLC (AZN.L)
Chart Events
Performance Outlook
| Previous Close | 10,586.00 |
| Open | 10,682.00 |
| Bid | 10,764.00 x 0 |
| Ask | 10,766.00 x 0 |
| Day's Range | 10,662.00 - 10,768.00 |
| 52 Week Range | 8,287.00 - 11,886.00 |
| Volume | |
| Avg. Volume | 2,140,069 |
| Market Cap | 166.792B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 101.53 |
| EPS (TTM) | 1.06 |
| Earnings Date | Feb 09, 2023 |
| Forward Dividend & Yield | 2.22 (2.09%) |
| Ex-Dividend Date | Aug 11, 2022 |
| 1y Target Est | 125.51 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AZN.L
Related Research
- Zacks
AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
- MarketWatch
AstraZeneca says Forxiga approved in EU for heart failure
AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.
- Reuters
PRESS DIGEST-British Business - Feb 6
The following are the top stories on the business pages of British newspapers. The Times - The UK is losing out on investment from AstraZeneca Plc to more competitive countries, Tom Keith-Roach, the head of the company, warned. - A British semiconductor company, IQE Plc could move overseas unless the government sets out its strategy for the sector in the next six months, its chief executive said.
